Palisade Bio Inc. (PALI): Price and Financial Metrics

Palisade Bio Inc. (PALI): $2.44

0.01 (+0.41%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add PALI to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#314 of 341

in industry

PALI Price/Volume Stats

Current price $2.44 52-week high $22.35
Prev. close $2.43 52-week low $2.18
Day low $2.35 Volume 256,100
Day high $2.89 Avg. volume 402,988
50-day MA $3.26 Dividend yield N/A
200-day MA $4.62 Market Cap 3.24M

PALI Stock Price Chart Interactive Chart >


Palisade Bio Inc. (PALI) Company Bio


Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier. The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In clinical studies, LB1148 has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and accelerating the time to return of postoperative bowel function. LB1148 is being investigated in a Phase 2 study to evaluate return of gastrointestinal function, post-operative ileus and intra-abdominal adhesions in subjects undergoing elective bowel resection. (copied from company website @ https://www.palisadebio.com/about-us/)


PALI Latest News Stream


Event/Time News Detail
Loading, please wait...

PALI Latest Social Stream


Loading social stream, please wait...

View Full PALI Social Stream

PALI Price Returns

1-mo -34.05%
3-mo -28.86%
6-mo -50.31%
1-year -71.92%
3-year -99.86%
5-year -100.00%
YTD -72.43%
2023 -88.65%
2022 -92.00%
2021 -75.38%
2020 -99.70%
2019 -99.20%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!